George Papakostas, MD
Associate Executive Director
Clinical Trials Network and Institute
Massachusetts General Hospital
Dr. George I. Papakostas is Associate Professor of Psychiatry at Harvard Medical School and Director of Treatment-Resistant Depression Studies in the Department of Psychiatry at Massachusetts General Hospital in Boston, Massachusetts. He is also field editor for Psychopharmacology for the World Journal of Biological Psychiatry and on the editorial board of the journal Psychiatry Research.
The focus of Dr Papakostas research includes the pharmacotherapy of major depressive disorder (MDD) including treatment-resistant depression, the study of the placebo effect and its relevance to clinical trial design in MDD, and the study of clinical and biologic markers of treatment outcome in MDD. Dr Papakostas has received numerous national and international research awards from sources including the American College of Neuropsychopharmacology and the American Psychiatric Association.
He is author or co-author of over 150 clinical and scientific publications and book chapters, and is author of the book entitled: Pharmacotherapy for Depression (World Scientific Publishing and Imperial College Press). Dr. Papakostas is often invited throughout the United States and abroad to lecture on a wide range topics pertaining to the treatment of depression. To date, he has delivered more than 100 lectures at National or International meetings in more than 30 countries.
Consultant: Abbott Laboratories, AstraZeneca PLC, Brainsway Ltd, Bristol-Myers Squibb Company, Cephalon Inc., Dey Pharma, L.P., Eli Lilly Co., GlaxoSmithKline, Evotec AG, H. Lundbeck A/S, Inflabloc Pharmaceuticals, Jazz Pharmaceuticals, Novartis Pharma AG, Otsuka Pharmaceuticals, PAMLAB LLC, Pfizer Inc., Pierre Fabre Laboratories, Ridge Diagnostics (formerly known as Precision Human Biolaboratories), Shire Pharmaceuticals, Sunovion Pharmaceuticals, Takeda Pharmaceutical Company LTD, Theracos, Inc., and Wyeth, Inc.
Honoraria: Abbott Laboratories, Astra Zeneca PLC, Bristol-Myers Squibb Company, Brainsway Ltd, Cephalon Inc., Dey Pharma, L.P., Eli Lilly Co., Evotec AG, GlaxoSmithKline, Inflabloc Pharmaceuticals, Jazz Pharmaceuticals, H. Lundbeck A/S, Novartis Pharma AG, Otsuka Pharmaceuticals, PAMLAB LLC, Pfizer, Pierre Fabre Laboratories, Ridge Diagnostics, Shire Pharmaceuticals, Sunovion Pharmaceuticals, Takeda Pharmaceutical Company LTD, Theracos, Inc., Titan Pharmaceuticals, and Wyeth Inc.
Research support: AstraZeneca PLC, Bristol-Myers Squibb Company, Forest Pharmaceuticals, the National Institute of Mental Health, PAMLAB LLC, Pfizer Inc., Ridge Diagnostics (formerly known as Precision Human Biolaboratories), Sunovion Pharmaceuticals, and Theracos, Inc.
Speaker’s bureau (not currently): BristolMyersSquibb Co and Pfizer, Inc.
No financial relationships have been disclosed.